8-K: Encompass Health Unveils Robust Growth Strategy and Strong Financial Performance in Latest Investor Update

Encompass Health Corporation has published its Investor Reference Book, detailing a strong business outlook, aggressive growth strategy, and solid financial health, reinforcing its leadership in the inpatient rehabilitation sector.

Summary

• Encompass Health Corporation (EHC) published an Investor Reference Book on June 25, 2025, providing an overview of the company, its industry, business outlook, growth strategy, and operational initiatives.
• The company reported approximately $5.4 billion in revenue and ~248,500 patient discharges in 2024, achieving an 8.3% total discharge growth.
• EHC is the largest owner and operator of Inpatient Rehabilitation Facilities (IRFs), with 168 hospitals as of June 13, 2025, including 67 joint ventures.
• Key growth targets include opening 6 to 10 de novo hospitals and adding 80 to 120 beds annually, aiming for a 6% to 8% discharge Compound Annual Growth Rate (CAGR).
• Recent growth includes 8 de novos and 46 bed additions in 2023, and 6 de novos and 147 bed additions in 2024.
• Financially, EHC reported Adjusted EBITDA of $1,103.7 million and Adjusted Free Cash Flow of $690.3 million for 2024.
• The company's leverage ratio improved to 2.3x at year-end 2024, down from 2.8x in 2023, and it had $953 million available on its $1 billion revolving credit facility as of March 31, 2025.
• Encompass Health consistently demonstrates high-quality clinical results, with 83.6% of patients discharged to the community in 2024, outperforming the Uniform Data System for Medical Rehabilitation (UDSMR) average of 81.1%.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook, strong financial performance, and clear growth strategies, emphasizing market leadership, attractive returns, and superior clinical outcomes, indicating very strong sentiment.

Positives

• Encompass Health is the largest provider of inpatient rehabilitation services, holding a leading position in the market.
• The company exhibits strong financial health, characterized by a well-managed balance sheet, substantial free cash flow generation ($690.3 million in 2024), and a declining leverage ratio (2.3x at YE 2024).
• EHC's growth strategy is robust, targeting 6-10 de novo hospitals and 80-120 bed additions annually, with 17 new hospitals announced and underway as of June 13, 2025.
• The company achieves attractive financial returns on its de novo and bed addition investments, fueling revenue and EBITDA growth.
• Clinical outcomes are superior to industry averages, with an 83.6% discharge-to-community rate in 2024 and lower rates of discharge to skilled nursing facilities (6.5%) and acute care hospitals (9.1%).
• Encompass Health provides cost-effective care, with an average estimated total payment per discharge of $25,357 for FY 2026, lower than non-EHC free-standing IRFs ($27,938) and hospital units ($28,376).
• The company benefits from an aging demographic, which drives increased demand for rehabilitation services, and a significant supply/demand imbalance in the IRF market.
• Strategic real estate ownership (79% of IRF real estate owned) enhances flexibility and avoids annual lease expense increases.
• EHC leverages advanced technology, including a proprietary clinical information system (Cerner EMR), Beacon management reporting, and patient/caregiver communication portals (MyEncompass Health app), to improve outcomes and efficiency.
• The company has a successful, long-standing joint venture strategy with major acute care hospital systems, facilitating integrated care delivery.

Risks

• Infectious disease outbreaks, such as COVID-19, could decrease patient volumes and revenues, and lead to staffing and supply shortages and associated cost increases.
• Changes in legal, regulatory, and administrative developments at federal, state, and local levels, including employment and environmental regulations, could impact operations.
• Demand for Encompass Health's services may be affected by downturns in the economy, consumer confidence, or capital markets.
• Potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of information systems, including unauthorized access to or theft of sensitive information.
• The company's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy.
• Changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for services by governmental or private payors.
• Changes in the regulation of the healthcare industry at federal and state levels, including national healthcare reform and deficit reduction, and the company's ability to adapt operations to these changes.
• Challenges in controlling costs, particularly labor and employee benefit costs, including group medical expenses.
• Difficulty in attracting and retaining nurses, therapists, and other healthcare professionals in a highly competitive environment with staffing shortages and potential union activity.
• General conditions in the economy and capital markets, including instability related to tariffs, trade wars, armed conflicts, governmental impasse over the federal budget, or an international sovereign debt crisis.
• Adverse outcomes of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health.
• The company's ability to realize construction cost and time savings from prefabrication of hospitals.
• Increases in Medicare audit activity, including increased use of sampling and extrapolation, potentially resulting in additional unpaid reimbursement claims and a backlog of appealed claims denials.
• Competitive pressures in the healthcare industry and Encompass Health's response thereto.
• Changes in Medicare regulations specific to inpatient rehabilitation, such as the review choice demonstration project and the Transforming Episode Accountability Model.

Future Outlook

Encompass Health projects continued strong growth, targeting 6 to 10 de novo hospitals and 80 to 120 bed additions annually, aiming for a 6% to 8% discharge CAGR. The company plans to further roll out in-house dialysis services to additional locations in 2025 and will regularly update its predictive models for readmission and fall risk, incorporating advances in predictive modeling to improve patient outcomes.

Management Comments

• Encompass Health believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures.
• Adjusted EBITDA is critical to the Company's assessment of its liquidity.
• Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company's capacity to reduce debt, pursue development activities, and return capital to its common stockholders.

Industry Context

The healthcare sector, particularly post-acute care, is an attractive market driven by a large, aging demographic (projected ~4% CAGR for age 75+ population) and a low conversion rate of eligible acute care patients to Inpatient Rehabilitation Facilities (IRFs) (~14.5%). The supply of licensed IRF beds has increased only modestly (4.2% since 2010) compared to the significant growth in the age 65+ population (60.5%), indicating a widening supply/demand imbalance. This fragmented sector presents significant opportunities for consolidation and joint ventures, which Encompass Health is actively pursuing. The company positions itself as a high-quality, cost-effective alternative to Skilled Nursing Facilities (SNFs) for intensive rehabilitation, aligning with broader healthcare trends emphasizing value-based care and efficient patient transitions.

Comparison to Industry Standards

• **Discharge to Community Rate**: Encompass Health achieved an 83.6% discharge to community rate in 2024, outperforming the Uniform Data System for Medical Rehabilitation (UDSMR) average of 81.1% for the same period.
• **Discharge to Skilled Nursing Facility (SNF) Rate**: Encompass Health's discharge to SNF rate was 6.5% in 2024, lower than the UDSMR average of 8.8%, indicating better patient recovery and reduced need for lower-acuity post-acute care.
• **Discharge to Acute Care Hospital Rate**: Encompass Health's discharge to acute care hospital rate was 9.1% in 2024, slightly better than the UDSMR average of 9.3%, suggesting effective management of patient conditions.
• **Cost-Effectiveness (Estimated Total Payment per Discharge)**: For FY 2026, Encompass Health's average estimated total payment per discharge is $25,357, which is significantly lower than free-standing (non-Encompass Health) IRFs at $27,938 and hospital units at $28,376, demonstrating superior cost efficiency.
• **Average Beds per IRF**: Encompass Health's IRFs average 66 beds, larger than non-Encompass Health free-standing IRFs (55 beds) and hospital units (25 beds), indicating economies of scale.
• **Average Medicare Discharges per IRF**: Encompass Health averages 926 Medicare discharges per IRF, substantially higher than non-Encompass Health free-standing IRFs (586 discharges) and hospital units (207 discharges), reflecting greater utilization and market penetration.
• **IRF vs. SNF Outcomes**: Inpatient Rehabilitation Facilities (IRFs) generally have a shorter average length of stay (12.5 days) compared to Skilled Nursing Facilities (SNFs) (34.5 days), and a higher discharge to community rate (67.2% for IRFs vs. 50.9% for SNFs), highlighting the clinical efficacy of IRF care.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong financial performance, consistent growth strategy, and the company's stated capacity to return capital through dividends and share repurchases.
• **Employees**: Potential for increased employment opportunities with the expansion of de novo hospitals and bed additions; continued focus on attracting and retaining healthcare professionals in a competitive labor market.
• **Customers (Patients)**: Enhanced access to high-quality, cost-effective inpatient rehabilitation services, improved clinical outcomes, and a better patient experience through technology integration and specialized care programs.
• **Suppliers**: Increased demand for construction materials, medical equipment, and operational supplies due to ongoing expansion and facility upgrades.
• **Creditors**: Strong balance sheet, manageable near-term debt maturities, and substantial free cash flow generation indicate a low credit risk profile, enhancing confidence for lenders.

Next Steps

• Continue to open 6 to 10 de novo hospitals per year.
• Continue to add 80 to 120 beds per year, including remote and satellite hospitals.
• Further roll out in-house dialysis services to additional locations in 2025.
• Regularly update predictive models (e.g., Readmission Prediction Model, Fall Risk Prediction Model) and incorporate advances in predictive modeling.
• Improve ease of learning and adoption of predictive tools for clinicians.
• Continue to evaluate and implement state-of-the-art therapy and clinical technologies.

Key Dates

Recommendation

Keywords

Inpatient Rehabilitation Facility, IRF, Healthcare, Post-Acute Care, SEC Filing, 8-K, Encompass Health, EHC, Financial Reporting, Investor Relations, De Novo, Joint Venture, Medicare, Medicaid, Adjusted EBITDA, Free Cash Flow, Clinical Outcomes, Patient Care, Hospital Management, Corporate Governance, Risk Management